Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
Links shared publicly online about this topic.
- 1,589total visits
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia
Genentech, inc., a wholly-owned member of the roche group (six: ro, rog; otcqx: rhhby), and biogen idec (nasdaq: biib) announced today that the u.s. food and drug administration (fda) issued a com
View full resource at medicalnewstoday.com
Tags: Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Drug, FDA, Rituxan, Roche Pharmaceuticals, Genentech, Biogen Idec
Most Recently Shared on November 20, 2009 at 9:20 am By:
Genentech And Biogen Idec Receive A Complete Response From The FDA For Rituxan For Chronic Lymphocytic Leukemia.. http://tinyurl.com/yhx227f
Advertisement
